Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Cutaneous Metastasis from a Carcinoma of the Bladder: Report of a Case
Wormer, Duncan C., Martin, William J., Emmett, John L., Devine, Kenneth D.

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 75 | Issue: 4 | Pages: 697-700

10.1016/s0022-5347(17)66867-8 | PMID 13307774 Get It

Treatment of Severe Nephrotic Syndrome With Meclofenamate: An Uncontrolled Pilot Study
Velosa, Jorge A., Donadío, James V., Wagoner, Richard D., Holley, Keith E., Offord, Kenneth P., Torres, Vicente E.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 135 | Issue: 3 | Pages: 659-660

10.1016/s0022-5347(17)45791-0 Get It

Bilateral Wilms Tumor
Blute, Michael L., Kelalis, Panayotis P., Offord, Kenneth P., Breslow, Norman, Beckwith, J. Bruce, D’Angio, Giulio J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 138 | Issue: 4 Part 2 | Pages: 968-973

10.1016/s0022-5347(17)43474-4 | PMID 2821293 Get It

Partial Epispadias in a Girl
Stanley, Kenneth, Symmonds, Richard E., Greene, Laurence F.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 89 | Issue: 3 | Pages: 439-441

10.1016/s0022-5347(17)64571-3 | PMID 13983401 Get It

Intracaval and Atrial Involvement with Nephroblastoma: Review of National Wilms Tumor Study-3
Ritchey, Michael L., Kelalis, Panayotis P., Breslow, Norman E., Offord, Kenneth P., Shochat, Stephen J., D’Angio, Giulio J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 140 | Issue: 5 Part 2 | Pages: 1113-1118

10.1016/s0022-5347(17)41975-6 | PMID 2846897 Get It

Re: The Evaluation of Microscopic Hematuria: A Population-Based Study, by I. M. Thompson J. Urol, 138: 1189–1190, 1987
Mohr, David N., Offord, Kenneth P., Melton, L. Joseph

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 140 | Issue: 6 | Pages: 1557-1558

10.1016/s0022-5347(17)42120-3 | PMID 3193541 Get It

Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma
Xi, Mian , Hallemeier, Christopher L. , Merrell, Kenneth W. , Murphy, Mariela A. Blum, Ho, Linus, Hofstetter, Wayne L. , Mehran, Reza J. , Lee, Jeffrey H. , Weston, Brian , Komaki, Ritsuko , Ajani, Jaffer A. , Hallemeier, Christopher Leigh , Liao, Zhongxing , Murphy, Mariela Blum, Bhutani, Manoop S. , Maru, Dipen Maheshbhai , Lin, Steven H. , Ajani, Jaffer A

Mayo Clinic

Annals of Surgery | June 17, 2017 | Volume: 268 | Issue: 2 | Pages: 289-295

10.1097/sla.0000000000002352 | PMID 28628563 Get It

Objective: To discern recurrence risk stratification and investigate its influence on postoperative surveillance in patients with esophageal adenocarcinoma (EAC) after neoadjuvant chemoradiotherapy (CRT). Background: Reports documenting recurrence risk stratification in EAC after neoadjuvant CRT are scarce. Methods: Between 1998 and 2014, 601 patients with EAC who underwent neoadjuvant CRT followed by esophagectomy were included for analysis. The pattern, site, timing, and frequency of the first recurrence and potential prognostic factors for developing recurrences were analyzed. This cohort was used as the training set to propose a recurrence risk stratification system, and the stratification was further validated in another cohort of 172 patients. Results: A total of 150 patients (25.0%) achieved pathologic complete response (pCR) after neoadjuvant CRT and the rest were defined as the non-pCR group (n = 451) in the training cohort. After a median follow-up of 63.6 months, the pCR group demonstrated a significantly lower locoregional (4.7% vs 19.1%) and distant recurrence rate (22.0% vs.44.6%) than the non-pCR group (P < 0.001). Based on independent prognostic factors, patients were stratified into 4 recurrence risk categories: pCR with clinical stage I/II, pCR with clinical stage III, non-pCR with pN0, and non-pCR with pN+, with corresponding 5-year recurrence-free survival rates of 88.7%, 65.8%, 55.3%, and 33.0%, respectively (P < 0.001). The risk stratification was reproducible in the validation cohort. Conclusions: We proposed a recurrence risk stratification system for EAC patients based on pathologic response and pretreatment clinical stage. Risk-based postoperative surveillance strategies could be developed for different risk categories.
A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults
Daver, Naval , McClain, Kenneth L. , Allen, Carl E. , Otrock, Zaher K. , Rojas‐Hernandez, Cristhiam M. , Blechacz, Boris, Wang, Sa , Minkov, Milen , Jordan, Michael B. , Rosée, Paul La , Kantarjian, Hagop M. , Parikh, Sameer A. , Daver, Naval , McClain, Kenneth L , Allen, Carl E , Kantarjian, Hagop

Mayo Clinic

Cancer | June 16, 2017 | Volume: 123 | Issue: 17 | Pages: 3229-3240

10.1002/cncr.30826 | PMID 28621800 Get It

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of severe immune activation and dysregulation resulting in extreme and often life‐threatening inflammation. HLH has been well recognized in pediatric populations, and most current diagnostic and therapeutic guidelines are based on pediatric HLH. Recently there has been recognition of HLH in adults, especially secondary to immune deregulation by an underlying rheumatologic, infectious, or malignant condition. This review is focused on malignancy‐associated HLH (M‐HLH), in which possible mechanisms of pathogenesis include severe inflammation, persistent antigen stimulation by the tumor cells, and loss of immune homeostasis because of chemotherapy, hematopoietic stem cell transplantation, or infection. Previously considered rare, M‐HLH may occur in up to 1% of patients with hematologic malignancies. M‐HLH is often missed or diagnosed late in most published studies, and it has been associated with a poor median survival of less than 2 months. Identification of the clinical and laboratory features specific to M‐HLH in adults may allow early detection, consultation with HLH experts, and intervention. Improved management of adult M‐HLH with optimal combinations of T‐lympholytic and immunosuppressive agents and the incorporation of novel agents based on the pediatric experience hopefully will improve outcomes in adults with M‐HLH. Cancer 2017;123:3229‐40. © 2017 American Cancer Society.
Fragile X‐associated Tremor/Ataxia Syndrome in an Adolescent Female
Mittal, Shivam Om , Mack, Kenneth J. , Bower, James H., Mack, Kenneth, Mittal, Shivam Om

Mayo Clinic

Movement Disorders Clinical Practice | May 28, 2017 | Volume: 4 | Issue: 5 | Pages: 778-780

10.1002/mdc3.12513 | PMID 30838288 Get It

View Supplementary Video 1
A novel community driven software for functional enrichment analysis of extracellular vesicles data
Pathan, Mohashin , Keerthikumar, Shivakumar , Chisanga, David , Ang, Ching‐Seng , Askenase, Philip W., Batagov, Arsen O., Benito‐Martín, Alberto , Clayton, Aled , Collino, Federica , Vizio, Dolores Di , Falcón‐Pérez, Juan Manuel , Fonseca, Pedro , Fonseka, Pamali , Fontana, Simona , Gho, Yong Song , Hendrix, An , Hoen, Esther N. M. Nolte-â€TMt, Iraci, Nunzio , Kastaniegaard, Kenneth , Kislinger, Thomas , Kowal, Joanna , Kurochkin, Igor V. , Leonardi, Tommaso , Liang, Yaxuan , Llorente, Alicia , Lunavat, Taral R. , Maji, Sayantan , Øverbye, Anders , Peinado, Héctor , Principe, Simona, Ronquist, G. , Royo, Félix , Sahoo, Susmita , Spinelli, Cristiana , Stensballe, Allan , Théry, Clotilde , Herwijnen, Martijn J. C. van , Wauben, Marca H. M. , Welton, Joanne L. , Zhao, Kening , Mathivanan, Suresh , Fonseca, Pedro , Fonseka, Pamali , Fontana, Simona , Iraci, Nunzio , Kastaniegaard, Kenneth , Kowal, Joanna , Leonardi, Tommaso , Øverbye, Anders , Peinado, Héctor , Spinelli, Cristiana , Welton, Joanne L , Alessandro, Riccardo , Camussi, Giovanni , Hoen, Esther N. M. Nolte‐‘t , Villafiorita‐Monteleone, Francesca , Panaretakis, Theocharis , Patel, Tushar , Pluchino, Stefano , Falcón-Perez, Juan Manual

Mayo Clinic

Journal of Extracellular Vesicles | May 26, 2017 | Volume: 6 | Issue: 1 | Pages: No page available

10.1080/20013078.2017.1321455 | PMID 28717418 Get It

ABSTRACTBioinformatics tools are imperative for the in depth analysis of heterogeneous high‐throughput data. Most of the software tools are developed by specific laboratories or groups or companies wherein they are designed to perform the required analysis for the group. However, such software tools may fail to capture “what the community needs in a tool”. Here, we describe a novel community‐driven approach to build a comprehensive functional enrichment analysis tool. Using the existing FunRich tool as a template, we invited researchers to request additional features and/or changes. Remarkably, with the enthusiastic participation of the community, we were able to implement 90% of the requested features. FunRich enables plugin for extracellular vesicles wherein users can download and analyse data from Vesiclepedia database. By involving researchers early through community needs software development, we believe that comprehensive analysis tools can be developed in various scientific disciplines.